DI CRISTO, VALENTINA
DI CRISTO, VALENTINA
Universita' degli Studi di MILANO
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation
2020-01-02 V. Di Cristo, F. Adorni, R. Maserati, M. Annovazzi Lodi, G. Bruno, P. Maggi, A. Volpe, P. Vitiello, C. Abeli, S. Bonora, M. Ferrara, M.V. Cossu, M.L. Oreni, E. Colella, S. Rusconi
Abacavir-induced liver toxicity
2016-04-04 M.D. Pezzani, C. Resnati, V. Di Cristo, A. Riva, C. Gervasoni
Factors involved in continuance of atazanavir-based regimens : Results from a cohort of HIV1-positive patients
2016-02-20 A. Giacomelli, L. Oreni, M. Franzetti, V. Di Cristo, E. Colella, A.L. Ridolfo, M. Galli, S. Rusconi
Gastrointestinal basidiobolomycosis: an emerging mycosis difficult to diagnose but curable: Case report and review of the literature
2019-01-17 M.D. Pezzani, V. Di Cristo, C. Parravicini, A. Sonzogni, C. Tonello, M. Franzetti, S. Sollima, M. Corbellino, M. Galli, L. Milazzo, S. Antinori
Orlistat: weight lost at cost of HIV rebound
2016-06-01 C. Gervasoni, D. Cattaneo, V. Di Cristo, S. Castoldi, E. Gervasi, E. Clementi, A. Riva
Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
2020-01-01 A. Antinori, M.V. Cossu, B. Menzaghi, G. Sterrantino, N. Squillace, V. Di Cristo, A. Cattelan, E. Foca, A. Castagna, G. Orofino, D. Valenti, G. D'Ettore, L. Aprea, S. Ferrara, M.E. Locatelli, G. Madeddu, E. Pontali, P. Scerbo, B. Rossetti, A. Uglietti, R. Termini, F. Rucci, A. Gori, D. Mancusi
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients
2012-11-11 A. Giacomelli, M. Franzetti, B. Vergani, L. Oreni, M. Morosi, V. Di Cristo, E. Colella, O. Viganò, M. Galli, S. Rusconi